[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hashimoto-thyroiditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hashimoto-thyroiditis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100636899","phase-2-colchicine-for-autoimmune-and-subacute-thyroiditis-100636899",false,"NCT07571681","Colchicine for Autoimmune and Subacute Thyroiditis","Colchicine as a Novel Anti-Inflammatory Strategy in Autoimmune and Subacute Thyroiditis: A Prospective Three-Arm Randomized Controlled Trial","COLTHYR","Inclusion Criteria:\n\n* Age 18 to 70 years\n* Newly diagnosed Hashimoto's thyroiditis or Subacute thyroiditis\n* Diagnosis confirmed clinically, biochemically, and ultrasonographically\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Severe renal impairment\n* Severe hepatic disease\n* Cytopenia\n* Active serious infection\n* Known hypersensitivity to colchicine\n* Chronic corticosteroid use within previous 30 days\n* Participation in another interventional trial\n* Any condition affecting safety or protocol adherence","ALL","18 Years","70 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","Thyroiditis includes inflammatory thyroid disorders such as Hashimoto's thyroiditis and subacute thyroiditis. These conditions may cause thyroid pain, neck tenderness, elevated inflammatory markers, thyroid dysfunction, fatigue, and recurrence. Current management includes observation, symptomatic treatment, nonsteroidal anti-inflammatory drugs, and corticosteroids. Although corticosteroids may be effective, relapse after tapering and treatment-related adverse effects remain limitations. Colchicine is hypothesized to reduce inflammatory activity and may improve biochemical and clinical recovery. This study will evaluate the efficacy and safety of low-dose colchicine compared with corticosteroid therapy and supportive care in adults with autoimmune or subacute thyroiditis.",[29,30,31],"Hashimoto Thyroiditis","Subacute Thyroiditis","Thyroiditis",[33,34,35,36,37,38,39,40],"Colchicine","Prednisolone","Autoimmune Thyroiditis","Inflammation","C-reactive protein","ESR","Thyroid Pain","Randomized Trial","NOT_YET_RECRUITING","2026-05-23",{"date":44,"type":45},"2026-05-28","ACTUAL",{"date":47,"type":22},"2026-07",{"date":49,"type":22},"2027-09",{"name":51,"class":52},"Mansoura University","OTHER"]